Concepedia

Publication | Closed Access

Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma

DOI

12

Citations

0

References

2023

Year

Takahito Sugase, Takashi Kanemura, Tomohira Takeoka, NORIHIRO MATSUURA, Yasunori Masuike, Naoki Shinno, Hisashi Hara, Masatoshi Kitakaze, Masahiko Kubo, Yosuke Mukai,
Anticancer Research

Abstract

Adjuvant nivolumab was more likely to prolong 1-year RFS in patients receiving neoadjuvant chemotherapy, especially in those with ypN1-2, and had acceptable adverse events.